NCT05228691 Prevalence of Long COVID-19 in the Canary Islands
| NCT ID | NCT05228691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Las Palmas de Gran Canaria |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2022-03-22 |
| Primary Completion | 2025-12-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2022-03-22 with a primary completion date of 2025-12-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With more than 246 million people diagnosed with coronavirus 2019 (COVID-19) around the world, many of whom have required medical attention for past 23 months, greater emphasis is being placed on post-acute care of COVID-19 survivors. According to recent data, millions of patients who have recovered from acute COVID-19 are experiencing persistent symptoms, which lead to disability and impaired activities of daily living. Various terms have been used to describe the condition of patients who do not return to their initial health status to include post-acute sequelae of COVID-19, such as post-acute COVID syndrome (PACS) and Long COVID. The growing global burden of COVID-19 suggests that the potential effects of Long COVID in public health are vast even if Long COVID is experienced by a small proportion of patients recovering from acute infection. The ability to identify patients at high risk for Long COVID and forecasting medical resource requirements is of important clinical utility in the present. In view of the large number of people surviving after infection with COVID-19 and that should require follow-up, determine which patients are at risk of have Long COVID and who require close monitoring is crucial. In this study, therefore, we set out to analyze what type of patient profile with COVID-19 who, after 12 weeks of having suffered the infection, experiences the signs and symptoms described by current literature.
Eligibility Criteria
Inclusion Criteria: * Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020). * Symptoms associated with COVID-19 at least after 12 weeks of its detection. * Adequate cognitive and physical level to understand and perform the tests evaluation. Exclusion Criteria: * Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19. * Fibromyalgia. * Chronic fatigue. * Neuromuscular disease. * Not having signed the informed consent. * Person undergoing treatment for active cancer.
Contact & Investigator
Aníbal Báez Suárez, PhD
PRINCIPAL INVESTIGATOR
University of Las Palmas de Gran Canaria
Frequently Asked Questions
Who can join the NCT05228691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05228691 currently recruiting?
Yes, NCT05228691 is actively recruiting participants. Contact the research team at anibal.baez@ulpgc.es for enrollment information.
Where is the NCT05228691 trial being conducted?
This trial is being conducted at Las Palmas de Gran Canaria, Spain.
Who is sponsoring the NCT05228691 clinical trial?
NCT05228691 is sponsored by University of Las Palmas de Gran Canaria. The principal investigator is Aníbal Báez Suárez, PhD at University of Las Palmas de Gran Canaria. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.